A descriptive case series of hepatotoxicity associated with CFTR modulators and possible relevance of pharmacogenetic polymorphisms in cystic fibrosis patients Authors: Clara Laffitte Redondo, Venceslas Bourdin, Abd El Kader Ait Tayeb, Sihem Benaboud, Inès Martins, Caroline Joyau, Myriam Benhamida, Isabelle Sermet‐Gaudelus, Clémence Martin, Pierre Régis Burgel, Céline Verstuyft, Laurent Chouchana, Estelle Ayme‐Dietrich Published: 2026 ABSTRACT Cystic fibrosis transmembrane conductance regulator (CFTR) modulators are widely used in patients with cystic fibrosis and significantly improve respiratory function and quality of life. However, their effectiveness may be limited by liver damage, which sometimes leads to treatment discontinuation, and the mechanisms underlying this remain poorly understood. This case series explores the role of genetic polymorphisms affecting the enzymes and transporters involved in their pharmacokinetics, as well as detoxification mechanisms (CYP3A4/CYP3A5/ABCB1/SLCO1B1/GSTP1/GSTM1/GSTT1). Six cases of hepatotoxicity under CFTR modulators were assessed using the RECAM score. Among the genetic polymorphisms assessed, CYP3A4*22 (rs35599367) allele had higher allele frequency than in the European population, which usually does not express CYP3A5. This genetic variant, reducing CYP3A activity, could decrease the elimination of CFTR modulators and increase the risk of liver toxicity. Other genetic factors may also be involved. Further studies are needed to confirm these results. What is already known about this subject CFTR modulators represent a true breakthrough in improving respiratory function and quality of life for patients with cystic fibrosis.Significant inter‐ and intra‐individual pharmacokinetic variability may explain certain adverse effects, limiting their use.Among these adverse effects, liver damage is often described and requires liver tests monitoring, sometimes necessitating discontinuation of the medication.The mechanisms underlying the hepatotoxicity of CFTR modulators are unknown. CFTR modulators represent a true breakthrough in improving respiratory function and quality of life for patients with cystic fibrosis. CFTR modulators represent a true breakthrough in improving respiratory function and quality of life for patients with cystic fibrosis. Significant inter‐ and intra‐individual pharmacokinetic variability may explain certain adverse effects, limiting their use. Significant inter‐ and intra‐individual pharmacokinetic variability may explain certain adverse effects, limiting their use. Among these adverse effects, liver damage is often described and requires liver tests monitoring, sometimes necessitating discontinuation of the medication. Among these adverse effects, liver damage is often described and requires liver tests monitoring, sometimes necessitating discontinuation of the medication. The mechanisms underlying the hepatotoxicity of CFTR modulators are unknown. The mechanisms underlying the hepatotoxicity of CFTR modulators are unknown. What this study adds We report here a case series of six patients with hepatotoxicity under CFTRm therapy.In these patients, we evidenced a higher‐than‐expected frequency of the decreased function allele CYP3A4*22 (rs35599367), compared to European population, and the non‐expression of CYP3A5.This case series hypothesize that the presence of CYP3A4*22 allele, by reducing CYP3A4 enzyme activity, could decrease the clearance of CFTR modulators and increase ivacaftor induced‐oxidative stress. We report here a case series of six patients with hepatotoxicity under CFTRm therapy. We report here a case series of six patients with hepatotoxicity under CFTRm therapy. In these patients, we evidenced a higher‐than‐expected frequency of the decreased function allele CYP3A4*22 (rs35599367), compared to European population, and the non‐expression of CYP3A5. In these patients, we evidenced a higher‐than‐expected frequency of the decreased function allele CYP3A4*22 (rs35599367), compared to European population, and the non‐expression of CYP3A5. This case series hypothesize that the presence of CYP3A4*22 allele, by reducing CYP3A4 enzyme activity, could decrease the clearance of CFTR modulators and increase ivacaftor induced‐oxidative stress. This case series hypothesize that the presence of CYP3A4*22 allele, by reducing CYP3A4 enzyme activity, could decrease the clearance of CFTR modulators and increase ivacaftor induced‐oxidative stress. INTRODUCTION The marketing of cystic fibrosis transmembrane conductance regulator (CFTR) modulators has been a real breakthrough in the treatment of patients with cystic fibrosis (CF). By increasing the expression and functionality of the CFTR chloride channel, CFTR modulators (CFTRm) improve both respiratory function tests and quality of life indicators, especially the combotherapy ivacaftor/tezacaftor/elexacaftor (IVA/TEZ/ELX). While most patients with CF tolerate this therapy well, some patients have presented adverse events. 1 Pharmacokinetics studies highlight large inter‐ and intra‐individual variability in CFTRm exposure, with the main sources of variability described as body weight, age, exocrine pancreatic insufficiency and CFTR genotype. 2 This pharmacokinetic variability, and specially elevated CFTRm exposure levels, could partially explain certain adverse events, 3 with some resulting from drug–drug interactions with CYP3A4/CYP3A5 strong inhibitors. 4 Among the most frequent adverse drug reactions associated with CFTRm, incidence of elevated liver tests is high, up to 10% of patients in clinical trials, between 5% and 10% in cohorts 1 , 5 requiring regular hepatic monitoring in treated patients. Although hepatotoxic mechanisms are unknown, hepatic necrosis with moderate mixed lobular inflammation on liver biopsies was reported, 6 suggesting the synthesis of toxic or immunogenic metabolites of CFTRm. A recent in vitro hepatotoxicity assays and quantitative systems toxicology modelling using DILIsym identified ivacaftor as the most significant driver of hepatotoxicity through the mechanisms of oxidative stress (ROS production) and mitochondrial dysfunction, due to electron transport chain inhibition. 7 Patients could be more sensitive to ROS production, depending on their level of glutathione S‐transferase (GST) protein expression. Besides, the deletion of GSTT1 and GSTM1 genes might influence susceptibility to drug‐induced liver injury (DILI), regardless of the type of drug involved. 8 Lumacaftor is not extensively metabolized, but it is a strong inducer of CYP3A4. Ivacaftor, tezacaftor and elexacaftor are each metabolized into active or partially active metabolites by CYP3A4 and CYP3A5, at 100%, 79% and 82%, respectively. 9 CFTRm may act as substrates for P‐glycoprotein and the OATP1B1/3 efflux transporter, 10 so genetic polymorphisms associated with ABCB1 and SLCO1B1 genes, which code for the P‐glycoprotein and OATP1B1 transporters, respectively, may contribute to pharmacokinetic variations in CFTRm. We therefore hypothesize that CYP3A4/CYP3A5, ABCB1, SLCO1B1 and GSTM1, GSTP1 and GSTT1 genetic polymorphisms could contribute to hepatotoxicity. MATERIALS AND METHODS Patients, data collection and clinical evaluation This retrospective case series consists of patients referred to our Pharmacovigilance Regional Centers (CRPV Paris Cochin‐Necker, CRPV Nantes) for suspected DILI associated with the use of CFTRm. Patients were frequently monitored for CF at French university hospitals (Cystic Fibrosis Competence Centers of Cochin/Necker, Trousseau [AP‐HP, Paris] and Nantes). Drug causality and the diagnosis was individually performed by two clinical pharmacologists (E.A.D., L.C.) specialized in drug safety using the RECAM score (revised electronic version of RUCAM; https://dilirecam.com/). This validated score for DILI takes into account biological and clinical evaluations: liver echography (to assess biliary obstruction), viral tests serologies and/or PCR (to diagnose a recent viral infection with hepatitis A, B, C and E, cytomegalovirus, Epstein–Barr or herpes virus) and clinical evaluation to analyse competing diagnoses (alcohol‐associated hepatitis, septic cholangitis, hypotension, malignant infiltration of the liver and competing medications). 11 Besides, pharmacogenetic analysis was performed to identify genetic factors associated with severity of adverse events, before reintroduction of CFTRm. Genotyping The patients' DNA was extracted from leukocytes isolated from whole blood collected in EDTA tubes (QIAsymphony, QIAGEN). The genetic polymorphisms investigated were as follows: SLCO1B1*5 (NM_006446.5: c.521 T > C, rs4149056), CYP3A4*22 (NM_017460.6: c.522‐191C > T, rs35599367), CYP3A5*3 (NM_000777.5: c.467‐1A > G, rs776746), ABCB1 (NM_001348946.2: c.2677G > A/T rs2032582 and c.3435C > T rs1045642) and GSTP1 (NM_000852.4: c. 313A > G, rs1695) and deletions of the GSTM1 and GSTT1 genes. Genotyping was performed by allele discrimination using Taqman probes in QuantStudio 7 (Thermo Fisher Scientific) for polymorphisms of the SLCO1B1, CYP3A4, CYP3A5 and ABCB1 genes. For genotyping of GST (M1, T1, P1), multiplex PCR was performed, followed by enzymatic digestion and detection of the results by agarose gel electrophoresis, as previously described. 12 The primers and PCR conditions are available on request. Statistical analysis Statistical and graphical analyses were performed using GraphPad Prism version 10.4 (GraphPad Software, Inc.). The data range has been specified for the demographic data. Although this case series was not designed to perform an association study, the comparison of the allele frequencies of each genetic polymorphisms investigated in this cohort and, those described in GnomAD for a non‐Finnish Caucasian population were performed using Fisher's exact tests. All tests were two‐tailed. The significance threshold retained was p < .05. In the context of exploratory analyses, no correction for multiple testing was used according to Bender and Lange. 13 Ethics Patients, or their legal representatives, have given their consent for genotyping and the use of their clinical data. The study was approved by the local institutional review board of the Cochin University Hospital under the number AAA‐2025‐10066 and complies with the general data protection regulation (GDPR, under the number 202602161715). RESULTS Case descriptions (Table 1) TABLE 1Summary of clinical characteristics of the case series of CFTR modulator‐induced liver injury.IDSex/age (years)CFTR mutationsType of CFTRmConcomitant drugsTime to onsetLiver test elevationsLiver examinationCompeting diagnosesDechallenge/rechallengeRECAM score 11 #1M/4ΔF508/Q220*IVA/TEZ/ELXAcetaminophen, in weight‐based doses, maximum 4 times per day, if fever23 days ALT > 5 × ULN R = 7.5 Ultrasounds: liver of normal size, homogeneous structure, no suspicious focal lesions, no biliary obstructionNegative diagnosis for autoimmune hepatitis: Anti‐nuclear, anti‐smooth muscle, anti‐LKM, anti‐LC1 antibodies negative Positive dechallenge 15 days after discontinuation of IVA/TEZ/ELX, favourable improvement in liver tests (ALT level becomes 2‐fold upper than normal values) Positive rechallenge Reintroduction of IVA/TEZ/ELX every 2 days resulting in increase in transaminase levels 15 days later (ALT = 2.7 × ULN). Positive viral influenzae A test, 20 days after reintroduction of IVA/TEZ/ELX, new episode of cytolysis (ALT = 20 × ULN) Two months after reintroduction of IVA/TEZ/ELX at half dose, new episode of cytolysis concomitant with administration of cotrimoxazole −1 (Possible) #2M/2.5ΔF508/ΔF508LUM/IVA15 days course of amoxicillin/clavulanic acid, stopped one week before transaminase elevation42 days ALT > 5 × ULN R = 9 Ultrasound: Normal liver with low‐fill gallbladder— Positive dechallenge Within 5 days of LUM/IVA discontinuation, favourable improvement in liver tests Positive rechallenge Reintroduction of LUM/IVA at progressive doses (half, three‐quarters and full dose): Increase in transaminase levels 93 days later (ALT > 5 × ULN) 2 (Possible) #3M/3ΔF508/G542*IVA/TEZ/ELX+ IVA boosterConcomitant treatment with amoxicillin and clavulanic acid for bronchial obstruction, initiated at the time of transaminase elevation270 days ALT > 5 × ULN R = 9.5 Ultrasound: liver of normal sizeNegative HAV and HCV serologies. HBV serology vaccinated. Negative CMV and EBV (IgM) serologies. Anti‐nuclear, anti‐smooth muscle, anti‐LKM, anti‐LC1 antibodies negative. Positive dechallenge Within 25 days of IVA/TEZ/ELX+ IVA booster discontinuation, favourable improvement in liver tests (10‐fold decrease in ALT, but ALT level remains more than 2 × ULN) Rechallenge (not assessable) No recurrence of symptoms after reintroduction of IVA/TEZ/ELX without booster, every 2 days −1 (Possible) #4M/43ΔF508/S13FIVA/TEZ/ELX+ IVA booster—44 days ALT > 5 × ULN R = 283 Abdominal‐pelvic scan: No hepatobiliary abnormalities detected Clinically, right hypochondrial pain and vomiting Negative HAV, HBV and HCV serologies; negative CMV, HSV 1–2, VZV, EBV and HEV PCR. Non‐dysmorphic hepatomegaly without focal lesions suggestive of malignancy Positive dechallenge Within 14 days of IVA/TEZ/ELX+ IVA booster discontinuation, favourable improvement in liver tests (10‐fold decrease in ALT, but ALT level remains more than 10 × ULN) Rechallenge (not assessable) No recurrence of symptoms following slow and progressive reintroduction of IVA, then IVA/TEZ, then IVA/TEZ/ELX without IVA booster 3 months after the event 9 (Highly probable) #5F/28ΔF508/c.1585‐9412A > GIVA/TEZ+ IVA boosterConcomitant treatment with azithromycin 3 times a week145 days ALT > 5 × ULN R = 20 Ultrasound: No hepatic colic Negative HAV and HEV serologies. Negative CMV, HSV 1–2, EBV PCR. No hepatobiliary abnormalities; no liver lesions nor portal hypertension Positive rechallenge Favourable improvement in liver tests, within 90 days of IVA/TEZ+ IVA booster discontinuation (ALT 2 × ULN 90 days after) Rechallenge (not assessable) No recurrence of symptoms following reintroduction of IVA/TEZ 105 days later, then IVA/TEZ/ELX −2 (Possible) #6F/26ΔF508/E474KIVA/TEZ/ELX + IVA booster—5 days ALT > 5 × ULN R = 23 —Negative HIV, HBV, HCV, HEV and parvovirus B19 serologies. Negative HSV 1–2, EBV, VZV, parvovirus B19 PCR. Positive dechallenge Favourable improvement in liver tests, within 10 days of IVA/TEZ/ELX + IVA booster discontinuation (sixfold decrease in ALT but ALT level remains 3.5 × ULN) Rechallenge (not assessable) Reintroduction of IVA/TEZ/ELX only at half dose 10 days after the event; a slight increase in liver function tests was observed, but no correction was subsequently made 2 (Possible) Abbreviations: CFTRm, CFTR modulator; ELX, elexacaftor; F, female; IVA, ivacaftor; LUM, lumacaftor; M, male; R, ratio of alanine aminotransferase (ALT)/alkaline phosphatase (ALP); TEZ, tezacaftor; ULN, upper limit of the normal. Summary of clinical characteristics of the case series of CFTR modulator‐induced liver injury. ALT > 5 × ULN R = 7.5 Positive dechallenge 15 days after discontinuation of IVA/TEZ/ELX, favourable improvement in liver tests (ALT level becomes 2‐fold upper than normal values) Positive rechallenge Reintroduction of IVA/TEZ/ELX every 2 days resulting in increase in transaminase levels 15 days later (ALT = 2.7 × ULN). Positive viral influenzae A test, 20 days after reintroduction of IVA/TEZ/ELX, new episode of cytolysis (ALT = 20 × ULN) Two months after reintroduction of IVA/TEZ/ELX at half dose, new episode of cytolysis concomitant with administration of cotrimoxazole −1 (Possible) ALT > 5 × ULN R = 9 Positive dechallenge Within 5 days of LUM/IVA discontinuation, favourable improvement in liver tests Positive rechallenge Reintroduction of LUM/IVA at progressive doses (half, three‐quarters and full dose): Increase in transaminase levels 93 days later (ALT > 5 × ULN) 2 (Possible) ALT > 5 × ULN R = 9.5 Positive dechallenge Within 25 days of IVA/TEZ/ELX+ IVA booster discontinuation, favourable improvement in liver tests (10‐fold decrease in ALT, but ALT level remains more than 2 × ULN) Rechallenge (not assessable) No recurrence of symptoms after reintroduction of IVA/TEZ/ELX without booster, every 2 days −1 (Possible) ALT > 5 × ULN R = 283 Abdominal‐pelvic scan: No hepatobiliary abnormalities detected Clinically, right hypochondrial pain and vomiting Negative HAV, HBV and HCV serologies; negative CMV, HSV 1–2, VZV, EBV and HEV PCR. Non‐dysmorphic hepatomegaly without focal lesions suggestive of malignancy Positive dechallenge Within 14 days of IVA/TEZ/ELX+ IVA booster discontinuation, favourable improvement in liver tests (10‐fold decrease in ALT, but ALT level remains more than 10 × ULN) Rechallenge (not assessable) No recurrence of symptoms following slow and progressive reintroduction of IVA, then IVA/TEZ, then IVA/TEZ/ELX without IVA booster 3 months after the event 9 (Highly probable) ALT > 5 × ULN R = 20 Negative HAV and HEV serologies. Negative CMV, HSV 1–2, EBV PCR. No hepatobiliary abnormalities; no liver lesions nor portal hypertension Positive rechallenge Favourable improvement in liver tests, within 90 days of IVA/TEZ+ IVA booster discontinuation (ALT 2 × ULN 90 days after) Rechallenge (not assessable) No recurrence of symptoms following reintroduction of IVA/TEZ 105 days later, then IVA/TEZ/ELX −2 (Possible) ALT > 5 × ULN R = 23 Positive dechallenge Favourable improvement in liver tests, within 10 days of IVA/TEZ/ELX + IVA booster discontinuation (sixfold decrease in ALT but ALT level remains 3.5 × ULN) Rechallenge (not assessable) Reintroduction of IVA/TEZ/ELX only at half dose 10 days after the event; a slight increase in liver function tests was observed, but no correction was subsequently made 2 (Possible) Abbreviations: CFTRm, CFTR modulator; ELX, elexacaftor; F, female; IVA, ivacaftor; LUM, lumacaftor; M, male; R, ratio of alanine aminotransferase (ALT)/alkaline phosphatase (ALP); TEZ, tezacaftor; ULN, upper limit of the normal. This case series of hepatotoxicity under CFTRm in patients with CF consisted in three children and three adults (Table 1). According to the patients genetic mutations of CFTR, four were treated with a combination of IVA/TEZ/ELX, including three in combination with a booster dose of ivacaftor, one was treated with lumacaftor/ivacaftor, and one received ivacaftor/tezacaftor in combination with a booster dose of ivacaftor. All patients experienced hepatocellular liver injury (R ALT/ALP > 5) with serum transaminases greater than five times the upper limit of the normal value during the first or subsequent exposures to CFTRm. Laboratory tests and imaging have ruled out other causes of hepatotoxicity. Drug causality, assessed with RECAM score was highly probable (RECAM > 8) for 1 case and possible (RECAM [−4;3]) for five cases. All patients showed regression of hepatotoxicity upon discontinuation of the CFTRm (positive dechallenge), and two of patients exhibited recurrence of the hepatotoxicity despite the progressive reintroduction of CFTRm at reduced doses (positive rechallenge). Pharmacogenetic analysis (Table 2) TABLE 2Allele frequencies of CYP3A4*22 (rs35599367), CYP3A5*3 (rs776746), SLCO1B1*5 (rs4149056), ABCB1 (3435C > T rs1045642, 2677G > T/A rs2032582) and GSTP1 (rs1695) genetic variants in GnomAD European non‐Finnish population and allele frequencies of GSTM1, GSTT1 genetic deletions in European population from 14 and allele frequencies of each genetic variants in this case series.Allele nomenclatureAllele frequency case series (%)Allele frequency GnomAD European non‐Finnish population (%) p value* CYP3A4*22 (rs35599367)254.9 0.019 CYP3A5*3 (rs776746)10093.30.62 SLCO1B1*5 (rs4149056)2515.30.41 ABCB1 c.3435 C > T rs104564241.746.21 ABCB1 c.2677 G > T rs20325825054.50.78 ABCB1 c.2677 G > A rs20325828.33.50.21 GSTP1 c.313A > G rs169533.334.61Allele nomenclatureAllele frequency case series (%)Allele frequency in European population (%) p value GSTM1 deletion50511 GSTT1 deletion33.3210.62* p < .05 (Fisher's exact tests). Allele frequencies of CYP3A4*22 (rs35599367), CYP3A5*3 (rs776746), SLCO1B1*5 (rs4149056), ABCB1 (3435C > T rs1045642, 2677G > T/A rs2032582) and GSTP1 (rs1695) genetic variants in GnomAD European non‐Finnish population and allele frequencies of GSTM1, GSTT1 genetic deletions in European population from 14 and allele frequencies of each genetic variants in this case series. p < .05 (Fisher's exact tests). Three patients were heterozygous carriers of the decreased‐function SLCO1B1*5 allele, associated with reduced OATP1B1 hepatic transporter activity, and one of these also carried a mutated genotype of ABCB1 (c.2677G > T/A and c.3435C > T). The allele frequency of genetic polymorphisms of ABCB1 (c.2677G > T/A and c.3435C > T) and SLCO1B1 (c.521 T > C) were not different from that observed in the European population (GnomAD European non‐Finnish; p > .05, for all three variants). Regarding metabolizing enzymes, the no‐function allele CYP3A5*3 (rs776746) was identified in all patients, consistent with a European ancestry profile. The decreased‐function allele CYP3A4*22 (rs35599367) was observed in three heterozygous patients, corresponding to an allele frequency of 21%, significantly higher than in the GnomAD non‐Finnish European population (p = .028) and higher than reported in any GnomAD ethnic group (maximum frequency 5.8%). For GST isoforms, deletions of GSTM1 and GSTT1 were observed in three (50%) and two patients (33%), respectively, while four (66%) patients carried the heterozygous GSTP1 variant (rs1695: c. 313A > G). One patient combined deletions of both GSTM1 and GSTT1 with heterozygosity for GSTP1 (rs1695: c. 313A > G). DISCUSSION In this case series of six patients with CFTRm‐induced hepatotoxicity, three were heterozygous for the CYP3A4*22 allele, and all were homozygous for the CYP3A5*3, that is, non‐expressors CYP3A5, suggesting an overall impaired CYP3A metabolic pathway in these patients. 15 , 16 , 17 Besides, we observed a higher‐than‐expected frequency of the CYP3A4*22 allele compared to general population. Altogether, as CYP3A is a major metabolic pathway for IVA/TEZ/ELX, this case series supports that this metabolic pathway may be of interest in the occurrence of CFTRm‐induced hepatotoxicity, likely to result in plasma concentrations. Even though the factors associated with interindividual variability in CFTRm are generally known (age, weight, pancreatic insufficiency, etc.), co‐administration with drugs that inhibit or induce CYP3A4 (clarithromycin, clofazimine, rifabutin, ritonavir, etc.) was implicated in several ETI dose modifications. 4 Several PB–PK models have been published to account for changes in pharmacokinetic parameters associated with CYP3A4 drug–drug interactions and to enable dose adjustment prior to the administration of CFTRm 18 , 19 ; however, no study has evaluated the influence of CYP3A4 genetic polymorphisms on the pharmacokinetic parameters of CFTRm and raises questions about the pharmacogenomic variations in the CYP3A4 gene, especially in patients who did not express CYP3A5, resulting in poor CYP3A activity. The majority of drug‐induced hepatotoxicity cases are idiosyncratic, and several genetic polymorphisms have been associated with them. Although NAT2 pharmacogenetic variants are well known to increase the risk of isoniazid‐induced hepatotoxicity in slow acetylators, 20 recent study highlights that CYP3A4*18 heterozygous have a higher risk of anti‐tuberculosis drug‐induced hepatotoxicity in Taiwan population. 21 This gain‐of‐function allele was supposed to increase the release of toxic metabolites. Moreover about atorvastatin metabolism, CYP3A4*22 and CYP3A5*3 variants by reducing enzyme activity, decrease hepatic clearance by approximately 20%–30%, raising hepatotoxicity risk via increased systemic exposure. 22 Once again, mitochondrial dysfunction impairing electron transport chain activity, causing ATP depletion and excessive ROS production, was suggested to induce hepatotoxicity. The presence of decreased function alleles on both efflux and influx transporters, for one patient, raises questions about the effect of these variants on the pharmacokinetics of the combination of lumacaftor/ivacaftor, the well‐tolerated combination CFTRm. 23 In this case series, only one patient expressed the three wild‐type forms of GSTT1, GSTM1 and GSTP1. Even though GST gene deletion is common in the general population, the association between GSTT1, GSTM1 and GSTP1 genetic polymorphisms and adverse drug reaction occurrence has been frequently reported 24 and should be investigated in patients with CF. Several conclusive evidences for association with hepatotoxic risk have been obtained with slow GSTM1 genotypes. 25 Among major mechanisms proposed for DILI based on the production of reactive metabolites, immune‐mediated hepatotoxicity and/or alterations in mitochondrial function and the drug‐induced liver injury from CF disease are based on the same pathophysiology. 26 Finally, an immune‐mediated mechanism may be hypothesized, especially since the incidence and prevalence of drug allergy is known to be higher in patients with CF. 27 A recent study assessed the types of reaction (e.g. rash, liver injury, drug fever), after CFTRm exposure and after re‐exposure, suggesting that drug allergy to CFTRm therapy is very rare and demonstrating that immune‐mediated reactions mainly appear as non‐immediate reactions with mild rashes. 28 Some lumacaftor‐ and ivacaftor‐specific T‐lymphocytes were detected in independent cases. 29 Necrosis and hepatocyte loss with mixed inflammatory infiltrate of lymphocytes were detected in one adult treated with tezacaftor/ivacaftor association, suggesting proliferative T‐cell response after ivacaftor and metabolite exposure in vitro at micromolar doses. 30 Specific human leucocyte antigen alleles could represent genetic risk factors for the development of DILI and should be evaluated. 31 Although this study has several methodological limitations and will have to be confirmed in cohort studies with a precise CFTRm‐induced adverse effects phenotyping, it highlights the contribution of CYP3A4*22 allele in CFTRm‐induced liver injury. We assume that this genetic variant by impairing CYP3A4 hepatic enzyme decreases ivacaftor clearance and improves the reactive oxygen species production. Moreover, therapeutic dose monitoring of CFTRm should be implemented to explore hepatotoxicity. Finally, pre‐emptive genotyping could be performed before CFTRm therapy to identify patients with CF with CYP3A4*22 allele and no CYP3A5 expression. These cases have been reported to the French Pharmacovigilance system under the numbers FR‐AFSSSAPS‐NT2024001591, FR‐AFSSSAPS‐NT2023001544, FR‐AFSSSAPS‐PV20212656, FR‐AFSSSAPS‐PV2025000637, FR‐AFSSSAPS‐PV2025000638, FR‐AFSSSAPS‐PV2025000639 and FR‐AFSSSAPS‐PV2025000640. AUTHOR CONTRIBUTIONS Clara Laffitte Redondo, Venceslas Bourdin, Abd El Kader Ait Tayeb, Céline Verstuyft, Laurent Chouchana and Estelle Ayme‐Dietrich wrote the manuscript. Clara Laffitte Redondo, Céline Verstuyft and Estelle Ayme‐Dietrich designed the research. Venceslas Bourdin, Inès Martins, Caroline Joyau, Myriam Benhamida, Isabelle Sermet‐Gaudelus, Clémence Martin, Pierre Régis Burgel, Laurent Chouchana and Estelle Ayme‐Dietrich performed the research. Abd El Kader Ait Tayeb, Sihem Benaboud, Céline Verstuyft, Laurent Chouchana and Estelle Ayme‐Dietrich analysed the data. CONFLICT OF INTEREST STATEMENT The authors declare no conflict of interest.